VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.11% | -29.25% | -50.52% | -0.99% | 6.01% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.75% | -14.87% | 29.95% | -54.61% | -47.16% |
| Change in Net Operating Assets | -16.18% | 421.04% | 133.81% | -426.05% | 4.57% |
| Cash from Operations | -5.75% | -0.34% | -6.25% | -55.38% | 0.29% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 366.48% | -125.36% | 632.92% | 94.28% | -- |
| Cash from Investing | 364.05% | -125.36% | 632.92% | 94.28% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -6,500.00% | 33.33% | 25.00% | -100.00% | 95.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -6,500.00% | 33.33% | 25.00% | -100.00% | 175,978.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 127.05% | -226.58% | 191.18% | -176.16% | 391.83% |